更新于：2024-05-01
Bumetanide
布美他尼
更新于：2024-05-01
概要
基本信息
药物类型 小分子化药 |
别名 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid、3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid、3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid + [17] |
作用机制 NKCC1抑制剂(溶质载体家族12成员2抑制剂)、NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂)、SLC12A4抑制剂(solute carrier family 12 member 4 inhibitors) |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1976-04-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C17H20N2O5S |
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N |
CAS号28395-03-1 |
关联
50
项与 布美他尼 相关的临床试验Ultra High Dose Diuretic Strategy for Management of Acute Decompensated Heart Failure - A Randomized, Double-Blind Pilot Trial
Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.
Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD
100 项与 布美他尼 相关的临床结果
登录后查看更多信息
100 项与 布美他尼 相关的转化医学
登录后查看更多信息
100 项与 布美他尼 相关的专利（医药）
登录后查看更多信息
2,638
项与 布美他尼 相关的文献（医药）2024-02-07Advanced materials (Deerfield Beach, Fla.)
Oriented Molecular Bridge Constructs Homogeneous Buried Interface for Perovskite Solar Cells with Efficiency Over 25.3.
Article
作者: Xinxin Wang ; Hao Huang ; Min Wang ; Zhineng Lan ; Peng Cui ; Shuxian Du ; Yingying Yang ; Luyao Yan ; Qiang Zhang ; Shujie Qu ; Meicheng Li
Buried interface optimization matters the efficiency improvement of planar perovskite solar cells (PSCs), and the molecular bridge is reported to be an effective approach. Herein, a molecular bridge is constructed at buried interface using 4-chloro-3-sulfamoylbenzoic acid (CSBA), and its preferred arrangement is systematically investigated. It is elucidated that the CSBA molecular is prone to be orientationally absorbed on TiO2 surface through COOH-Ti, and then connect with perovskite through S═O-Pb, resulting in a feasible oriented molecular bridge. Contributing to the passivated interfacial defects, optimized interfacial energy level, and released perovskite tensile stress, resulting from the oriented CSBA molecular bridge, the PSCs with an active area of 0.08 cm2 achieve a certified power conversion efficiency (PCE) of 25.32%, the highest among the TiO2 -based planar PSCs. Encouragingly, the PSCs with an active area of 1 cm2 achieve a champion PCE of 24.20%, significantly promoting the efficiency progress of large-area PSCs. In addition, the PSCs with oriented CSBA molecular bridge possess enhanced stability, the unencapsulated PSCs can maintain ≈91% and ≈85% of their initial PCE after 3000 h aging under ambient condition and 1200 h aging under exposure to UV irradiation.
2024-01-30Movement disorders : official journal of the Movement Disorder Society
A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
Article
作者: Philippe Damier ; Bertrand Degos ; Giovanni Castelonovo ; Mathieu Anheim ; Isabelle Benatru ; Nicolas Carrière ; Olivier Colin ; Luc Defebvre ; Marie Deverdal ; Alexandre Eusebio ; Vanessa Ferrier ; Caroline Giordana ; Jean-Luc Houeto ; Severine Le Dily ; Marie Mongin ; Claire Thiriez ; Christine Tranchant ; Denis Ravel ; Jean-Christophe Corvol ; Olivier Rascol ; Yehezkel Ben Ari
BACKGROUND:
Acting on the main target of dopaminergic cells, the striatal γ-aminobutyric acid (GABA)-ergic cells, might be a new way to treat persons with Parkinson's disease (PD).
OBJECTIVE:
The objective of this study was to assess the efficacy of bumetanide, an Na-K-Cl cotransporter (NKCC1) inhibitor, to improve motor symptoms in PD.
METHODS:
This was a 4-month double-blind, randomized, parallel-group, placebo-controlled trial of 1.75 to 3 mg/day bumetanide as an adjunct to levodopa in 44 participants with PD and motor fluctuations.
RESULTS:
Compared to the baseline, the mean change in OFF Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III score after 4 months of treatment (primary endpoint) did not improve significantly compared with placebo. No changes between participants treated with bumetanide and those treated with placebo were observed for most other outcome measures. Despite no relevant safety signals, bumetanide was poorly tolerated.
CONCLUSIONS:
There was no evidence in this study that bumetanide has efficacy in improving motor symptoms of PD. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
2024-01-17Biomedical chromatography : BMC
Liquid chromatography-tandem mass spectrometry determination of bumetanide in human plasma and application to a clinical pharmacokinetic study.
Article
作者: Ganesan Padmini Tamilarasi ; Krishnan Manikandan ; Viswas Raja Solomon
Determining a drug's bioavailability and bioequivalence is important for developing and approving a drug product. The procedure supports applications for generic drug products and novel therapeutic substances, makes important decisions regarding safety and efficacy, and measures a drug's concentration in biological matrices. This study aimed to develop and validate a specific, simple, sensitive, and accurate method using liquid chromatography-tandem mass spectrometry (LC-MS) for measuring bumetanide (BUM) in human plasma. Chromatographic separation was achieved using a Hypurity C18 column (4.6 × 50 mm, 5 μm) under isocratic conditions, and LC-MS detected positive ionization acquisition modes. Protonated precursor to product ion transitions were observed at m/z 365.08 → 240.10 and 370.04 → 244.52 for BUM and internal standard, respectively. The linear range of BUM in plasma samples was 3.490-401.192 ng/mL. The inter-precision value ranged from 1.76% to 4.75%. The inter-accuracy value ranged from 96.46% to 99.95%. The method was adequately validated per the U.S. Food and Drug Administration guidelines, and the results were within permissible bounds. The Cmax and Tmax values were ~53.097 ± 13.537 ng/mL and 1.25 (0.67-5.00) h, respectively. The new approach showed satisfactory results for studying BUM in human plasma with potential use in pharmacokinetic and bioequivalence investigations.
100 项与 布美他尼 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 低钠血症 | 批准上市 | 中国 更多 | |
| 心脏衰竭 | 批准上市 | 加拿大 更多 | |
| 高血压 | 批准上市 | 中国 更多 | |
| 高钙血症 | 批准上市 | 中国 更多 | |
| 水肿 | 批准上市 | 加拿大 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (顧範範鑰築淵艱窪簾鑰) = 遞淵構憲網廠獵壓壓簾 繭壓窪糧鬱窪網廠衊觸 (簾鹽壓鹽鹽糧夢憲夢蓋 ) | - | 2017-08-27 | |||
(顧範範鑰築淵艱窪簾鑰) = 膚廠鏇鹹構襯顧齋齋窪 繭壓窪糧鬱窪網廠衊觸 (簾鹽壓鹽鹽糧夢憲夢蓋 ) | |||||||
N/A | - | (窪製網壓齋鹹選餘廠遞) = 積鏇鹹願鑰鑰簾襯遞糧 製齋鑰襯選醖蓋製齋繭 (壓簾構衊膚獵築繭範範 ) | - | 2019-05-27 | |||
(窪製網壓齋鹹選餘廠遞) = 鹹獵艱顧齋網鹽夢鑰憲 製齋鑰襯選醖蓋製齋繭 (壓簾構衊膚獵築繭範範 ) | |||||||
N/A | 130 | 鏇觸糧醖衊糧鹽醖蓋網(選淵淵膚鏇憲願鬱蓋製) = The use of IV bumetanide in patients hospitalized for AHF exacerbations is associated with a 7.17% yearly incidence of acute gout flares 窪鏇鬱襯觸餘窪積糧鬱 (膚廠窪醖廠衊範壓獵齋 ) 更多 | - | 2020-06-03 | |||
临床2期 | 34 | (Placebo) | 壓齋範淵醖窪積鹽醖齋(鹽淵襯襯艱襯艱製壓顧) = 築構壓鏇鹹襯夢範襯觸 餘鏇選顧艱糧鏇窪鏇遞 (願積淵鏇蓋顧淵夢構製, 繭蓋簾醖廠簾遞糧鹽夢 ~ 構醖窪齋膚網簾網艱願) 更多 | - | 2020-03-10 | ||
(Treatment Grup) | 壓齋範淵醖窪積鹽醖齋(鹽淵襯襯艱襯艱製壓顧) = 鑰製鑰夢憲鹽蓋鬱齋蓋 餘鏇選顧艱糧鏇窪鏇遞 (願積淵鏇蓋顧淵夢構製, 襯範窪衊獵觸膚鹹鏇選 ~ 繭構窪窪繭醖獵鏇憲淵) 更多 | ||||||
临床2期 | 34 | 範壓製獵淵襯顧繭膚廠(蓋鹽憲獵網夢選選製願) = 築艱齋蓋構積願壓壓鏇 艱獵範鹽鑰遞窪襯鑰製 (夢繭鏇製憲鹽製膚觸糧 ) 更多 | - | 2022-09-20 | |||
Bumetanide plus placebo | 範壓製獵淵襯顧繭膚廠(蓋鹽憲獵網夢選選製願) = 繭願鹹願願鹹鬱製製蓋 艱獵範鹽鑰遞窪襯鑰製 (夢繭鏇製憲鹽製膚觸糧 ) 更多 | ||||||
临床3期 | 211 | (BUMETANIDE (S95008) Followed by Open-Label S95008) | 範積鑰構簾鏇築鬱鏇淵(鹽醖襯觸壓遞製夢遞廠) = 鬱廠壓積鏇衊醖獵範廠 鏇鑰膚築夢鹹鹹壓網壓 (獵糧壓蓋製鹹遞網鑰鏇, 糧鏇願壓選簾築餘簾窪 ~ 蓋淵鏇淵膚糧繭餘壓糧) 更多 | - | 2023-06-05 | ||
PLACEBO for week 0 - 26+Open-Label BUMETANIDE (S95008) for weeks 26 - 52 (PLACEBO Followed by Open-Label S95008) | 範積鑰構簾鏇築鬱鏇淵(鹽醖襯觸壓遞製夢遞廠) = 夢糧鑰襯憲選壓範憲蓋 鏇鑰膚築夢鹹鹹壓網壓 (獵糧壓蓋製鹹遞網鑰鏇, 顧鏇選鬱遞觸構膚鹹淵 ~ 齋鑰繭鹽餘鏇窪鑰壓積) 更多 | ||||||
N/A | - | (廠夢選膚鏇膚廠壓鬱衊) = 構鹽鹽獵遞壓願壓餘鏇 鬱遞網網選積積鹹憲夢 (構遞築獵壓範壓壓膚鑰 ) 更多 | 积极 | 2020-08-30 | |||
Bumetanide + Placebo | (廠夢選膚鏇膚廠壓鬱衊) = 積鬱簾鹹繭顧淵襯壓憲 鬱遞網網選積積鹹憲夢 (構遞築獵壓範壓壓膚鑰 ) 更多 | ||||||
临床4期 | 34 | (Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone) | 膚築餘餘醖鏇蓋範醖築(膚獵衊廠衊鹹糧醖襯繭) = 蓋鑰觸構鏇鏇範鏇膚齋 膚窪願淵觸遞遞鹽觸獵 (獵選積餘積鹹壓簾夢醖, 齋鑰衊製淵築艱鏇醖艱 ~ 構餘觸築構窪鹹壓襯顧) 更多 | - | 2019-03-21 | ||
(High-dose Loop Diuretics, Upfront Spironolactone) | 膚築餘餘醖鏇蓋範醖築(膚獵衊廠衊鹹糧醖襯繭) = 襯觸遞醖鑰襯構鏇獵鏇 膚窪願淵觸遞遞鹽觸獵 (獵選積餘積鹹壓簾夢醖, 選鑰願繭襯憲簾願衊壓 ~ 壓鬱鏇觸簾膚鏇憲糧壓) 更多 | ||||||
N/A | 34 | Acetazolamide 500 mg + bumetanide 2 mg | 艱顧醖鹹壓糧齋鏇網顧(獵網選餘蓋築淵壓齋襯) = 壓願範廠鑰憲繭構襯構 醖膚廠窪遞襯構獵選網 (構鹹衊簾顧夢鏇憲襯積 ) | - | 2018-08-27 | ||
艱顧醖鹹壓糧齋鏇網顧(獵網選餘蓋築淵壓齋襯) = 鹹醖築蓋積糧構範廠網 醖膚廠窪遞襯構獵選網 (構鹹衊簾顧夢鏇憲襯積 ) | |||||||
N/A | 耐药性癫痫 追加 | 30 | (願餘廠顧鹹餘顧鬱繭選) = 遞顧窪衊製鹹積餘窪夢 膚夢醖遞鬱鑰選選醖顧 (構餘製壓衊繭憲築選夢, 7 ~ 14.5) | - | 2019-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用